Suppr超能文献

肢端肥大症患者重复经蝶窦手术后的手术结果。

Surgical outcome after repeated transsphenoidal surgery in acromegaly.

作者信息

Long H, Beauregard H, Somma M, Comtois R, Serri O, Hardy J

机构信息

Department of Medicine, University of Montreal, Notre-Dame Hospital, Quebec, Canada.

出版信息

J Neurosurg. 1996 Aug;85(2):239-47. doi: 10.3171/jns.1996.85.2.0239.

Abstract

Transsphenoidal selective adenomectomy is the most efficient primary treatment for acromegaly. However, management of persistent or recurrent disease remains controversial. The objective of the present study was to evaluate the early and long-term efficacy and safety of a second transsphenoidal surgery performed in those cases. The results of a retrospective study of 16 patients undergoing reoperation by the senior author (J.H.) between 1970 and 1991 are reported. Reoperation was performed for persistent or progressive acromegaly in 11 patients, visual impairment in four, and disease recurrence in one. Normalization of growth hormone (GH) was defined as a basal GH level of less than 5 micrograms/L and suppression to less than 2 micrograms/L during the oral glucose tolerance test. Long-term follow-up data were available in 15 patients. The second transsphenoidal surgery induced a greater than 50% decrease of GH level in 11 patients. Three (19%) of 16 patients were cured according to the authors' criteria and remained so after 2, 7, and 20 years. Two more patients had a postoperative basal GH level of less than 5 micrograms/L but incomplete suppression during the oral glucose tolerance test. Thus, a total of five patients (31%) achieved a basal GH of less than 5 micrograms/L. One other patient who had no initial improvement after the second transphenoidal surgery had spontaneous normalization of his GH level after 13 years. The following complications of the second surgery occurred in three patients: one subarachnoid hemorrhage, two new visual field defects, one cranial nerve palsy, and one meningitis. Moreover, 10 patients (62.5%) developed one or more new pituitary hormone deficiencies. In conclusion, reoperation for persistent or recurrent acromegaly has low success and high complication rates. According to the authors' experience, this procedure should be reserved for patients unresponsive to other forms of therapy or with progressive visual impairment despite medical therapy.

摘要

经蝶窦选择性腺瘤切除术是肢端肥大症最有效的主要治疗方法。然而,持续性或复发性疾病的管理仍存在争议。本研究的目的是评估在这些病例中进行二次经蝶窦手术的早期和长期疗效及安全性。报告了对1970年至1991年间由资深作者(J.H.)进行再次手术的16例患者的回顾性研究结果。11例患者因持续性或进行性肢端肥大症接受再次手术,4例因视力障碍,1例因疾病复发。生长激素(GH)正常化定义为基础GH水平低于5微克/升,口服葡萄糖耐量试验期间抑制至低于2微克/升。15例患者有长期随访数据。二次经蝶窦手术使11例患者的GH水平下降超过50%。根据作者的标准,16例患者中有3例(19%)治愈,在2年、7年和20年后仍保持治愈状态。另外2例患者术后基础GH水平低于5微克/升,但口服葡萄糖耐量试验期间抑制不完全。因此,共有5例患者(31%)的基础GH低于5微克/升。另1例患者在二次经蝶窦手术后最初无改善,但13年后GH水平自发恢复正常。二次手术发生了以下并发症:1例蛛网膜下腔出血、2例新的视野缺损、1例颅神经麻痹和1例脑膜炎。此外,10例患者(62.5%)出现一种或多种新的垂体激素缺乏。总之,对持续性或复发性肢端肥大症进行再次手术成功率低且并发症发生率高。根据作者的经验,该手术应仅用于对其他治疗形式无反应或尽管接受药物治疗仍有进行性视力障碍的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验